Atrial fibrillation (AF) is the most common arrhythmia in the world, and its management relies on restoring sinus rhythm through external electrical shock and controlling the heart rate. This procedure should be performed under sedation with strict monitoring of blood pressure and saturation after the elimination of thrombus in the left atrium. Objective: The aim of this article is to provide an overview of the impact of anticoagulation and imaging in the periprocedural period, the modalities, and the complications associated with electrical cardioversion (ECV). Research Method: A review of recent literature was conducted using medical databases such as PubMed and Scopus. Searches were performed on articles published between 2003 and 2024, focusing on the new ESC guidelines for 2024. The keywords used included “electrical cardioversion”, “atrial fibrillation”, “orthogonal cardioversion” and “anticoagulation”. Inclusion criteria encompassed clinical trials, meta-analyses, and literature reviews, while studies addressing other treatment forms for AF or lacking information on ECV were excluded. Relevant data were extracted and synthesized to provide an overview of the modalities and complications related to ECV in the context of AF. Results and Conclusion: The use of high-energy biphasic shocks significantly improves rhythm control success and also reduces the incidence of ventricular fibrillation. Furthermore, orthogonal electrical cardioversion (OECV) has proven effective for cases of AF refractory to standard protocols, allowing for a lower defibrillation threshold and promoting better current distribution. However, complications must be considered, particularly thromboembolic events in non-anticoagulated patients. Other complications, such as bradycardia and recurrence of AF, may arise post-procedure. It is therefore crucial to ensure adequate anticoagulation before and after ECV, as well as continuous monitoring, to minimize these risks and optimize clinical outcomes.
References
[1]
Cheniti, G., Vlachos, K., Pambrun, T., Hooks, D., Frontera, A., Takigawa, M., et al. (2018) Atrial Fibrillation Mechanisms and Implications for Catheter Ablation. FrontiersinPhysiology, 9, Article 1458. https://doi.org/10.3389/fphys.2018.01458
[2]
Van Gelder, I.C., Rienstra, M., et al. (2024) 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal, 45, 3314-3414.
[3]
Chung, M.K., Refaat, M., Shen, W., Kutyifa, V., Cha, Y., Di Biase, L., et al. (2020) Atrial Fibrillation. JournaloftheAmericanCollegeofCardiology, 75, 1689-1713. https://doi.org/10.1016/j.jacc.2020.02.025
[4]
Schnabel, R.B., Yin, X., Gona, P., Larson, M.G., Beiser, A.S., McManus, D.D., et al. (2015) 50 Year Trends in Atrial Fibrillation Prevalence, Incidence, Risk Factors, and Mortality in the Framingham Heart Study: A Cohort Study. TheLancet, 386, 154-162. https://doi.org/10.1016/s0140-6736(14)61774-8
[5]
Barra, S. and Providência, R. (2020) Anticoagulation in Atrial Fibrillation. Heart, 107, 419-427. https://doi.org/10.1136/heartjnl-2020-316728
[6]
Brandes, A., Crijns, H.J.G.M., Rienstra, M., Kirchhof, P., Grove, E.L., Pedersen, K.B., et al. (2020) Cardioversion of Atrial Fibrillation and Atrial Flutter Revisited: Current Evidence and Practical Guidance for a Common Procedure. EPEuropace, 22, 1149-1161. https://doi.org/10.1093/europace/euaa057
[7]
Yu, S., Zhang, H. and Li, H. (2021) Cardiac Computed Tomography versus Transesophageal Echocardiography for the Detection of Left Atrial Appendage Thrombus: A Systemic Review and Meta-Analysis. Journal of the American Heart Association, 10, e022505. https://doi.org/10.1161/jaha.121.022505
[8]
Beigel, R., Wunderlich, N.C., Ho, S.Y., Arsanjani, R. and Siegel, R.J. (2014) The Left Atrial Appendage: Anatomy, Function, and Noninvasive Evaluation. JACC: Cardiovascular Imaging, 7, 1251-1265. https://doi.org/10.1016/j.jcmg.2014.08.009
[9]
Davenport, M.S., Perazella, M.A., Yee, J., Dillman, J.R., Fine, D., McDonald, R.J., et al. (2020) Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease. Kidney Medicine, 2, 85-93. https://doi.org/10.1016/j.xkme.2020.01.001
[10]
Martinez, M.W., Kirsch, J., Williamson, E.E., Syed, I.S., Feng, D., Ommen, S., et al. (2009) Utility of Nongated Multidetector Computed Tomography for Detection of Left Atrial Thrombus in Patients Undergoing Catheter Ablation of Atrial Fibrillation. JACC: CardiovascularImaging, 2, 69-76. https://doi.org/10.1016/j.jcmg.2008.09.011
[11]
Vira, T., Pechlivanoglou, P., Connelly, K., Wijeysundera, H.C. and Roifman, I. (2018) Cardiac Computed Tomography and Magnetic Resonance Imaging vs. Transoesophageal Echocardiography for Diagnosing Left Atrial Appendage Thrombi. EPEuropace, 21, e1-e10. https://doi.org/10.1093/europace/euy142
[12]
Camm, A.J., Naccarelli, G.V., Mittal, S., Crijns, H.J.G.M., Hohnloser, S.H., Ma, C., et al. (2022) The Increasing Role of Rhythm Control in Patients with Atrial Fibrillation. JournaloftheAmericanCollegeofCardiology, 79, 1932-1948. https://doi.org/10.1016/j.jacc.2022.03.337
[13]
Hatala, R. (2021) Rhythm Control in Asymptomatic ‘Early’ Atrial Fibrillation: Birth of a New Paradigm? EuropeanHeartJournal, 43, 1231-1233. https://doi.org/10.1093/eurheartj/ehab811
[14]
Willems, S., Borof, K., Brandes, A., Breithardt, G., Camm, A.J., Crijns, H.J.G.M., et al. (2021) Systematic, Early Rhythm Control Strategy for Atrial Fibrillation in Patients with or without Symptoms: The EAST-AFNET 4 Trial. EuropeanHeartJournal, 43, 1219-1230. https://doi.org/10.1093/eurheartj/ehab593
[15]
Metzner, A., Suling, A., Brandes, A., Breithardt, ,.G., Camm, A.J., Crijns, H.J.G.M., et al. (2021) Anticoagulation, Therapy of Concomitant Conditions, and Early Rhythm Control Therapy: A Detailed Analysis of Treatment Patterns in the EAST—AFNET 4 Trial. EPEuropace, 24, 552-564. https://doi.org/10.1093/europace/euab200
[16]
Nguyen, S.T., Belley-Côté, E.P., Ibrahim, O., Um, K.J., Lengyel, A., Adli, T., et al. (2022) Techniques Improving Electrical Cardioversion Success for Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. EPEuropace, 25, 318-330. https://doi.org/10.1093/europace/euac199
[17]
Schmidt, A.S., Lauridsen, K.G., et al. (2019) Maximum-Fixed Energy Shocks for Cardioverting Atrial Fibrillation. EuropeanHeartJournal, 41, 626-631.
[18]
Schmidt, A.S., Lauridsen, K.G., Møller, D.S., et al. (2021) Anterior-Lateral versus Anterior-Posterior Electrode Position for Cardioverting Atrial Fibrillation. Circulation, 144, 1995-2003.
[19]
Boos, C., Thomas, M., Jones, A., Clarke, E., Wilbourne, G. and More, R. (2003) Higher Energy Monophasic DC Cardioversion for Persistent Atrial Fibrillation: Is It Time to Start at 360 Joules? AnnalsofNoninvasiveElectrocardiology, 8, 121-126. https://doi.org/10.1046/j.1542-474x.2003.08205.x
[20]
Boodhoo, L., Mitchell, A.R.J., Bordoli, G., Lloyd, G., Patel, N. and Sulke, N. (2007) DC Cardioversion of Persistent Atrial Fibrillation: A Comparison of Two Protocols. InternationalJournalofCardiology, 114, 16-21. https://doi.org/10.1016/j.ijcard.2005.11.108
[21]
Velázquez-Rodríguez, E., Pérez-Sandoval, H.A. and Rangel-Rojo, F.J. (2020) Orthogonal Electrical Cardioversion in Atrial Fibrillation Refractory to Biphasic Shocks: A Case Series. EuropeanHeartJournal—CaseReports, 4, 1-5. https://doi.org/10.1093/ehjcr/ytaa343
[22]
Itäinen-Strömberg, S., Lehto, M., Halminen, O., Putaala, J., Haukka, J., Lehtonen, O., et al. (2024) Thromboembolic and Bleeding Complications after Elective Cardioversion of Atrial Fibrillation: A Nationwide Cohort Study. Europace, 26, euae131. https://doi.org/10.1093/europace/euae131
[23]
Airaksinen, K.E.J., Grönberg, T., Nuotio, I., Nikkinen, M., Ylitalo, A., Biancari, F., et al. (2013) Thromboembolic Complications after Cardioversion of Acute Atrial Fibrillation. JournaloftheAmericanCollegeofCardiology, 62, 1187-1192. https://doi.org/10.1016/j.jacc.2013.04.089
[24]
Grönberg, T., Nuotio, I., Nikkinen, M., Ylitalo, A., Vasankari, T., Hartikainen, J.E.K., et al. (2013) Arrhythmic Complications after Electrical Cardioversion of Acute Atrial Fibrillation: The FinCV Study. EPEuropace, 15, 1432-1435. https://doi.org/10.1093/europace/eut106
[25]
Rasmussen, P.V., Blanche, P., Dalgaard, F., Gislason, G.H., Torp-Pedersen, C., Tønnesen, J., et al. (2022) Electrical Cardioversion of Atrial Fibrillation and the Risk of Brady-Arrhythmic Events. AmericanHeartJournal, 244, 42-49. https://doi.org/10.1016/j.ahj.2021.10.182
[26]
Rasmussen, P.V., Nielsen, J.B., Skov, M.W., Pietersen, A., Graff, C., Lind, B., et al. (2017) Electrocardiographic PR Interval Duration and Cardiovascular Risk: Results from the Copenhagen ECG Study. CanadianJournalofCardiology, 33, 674-681. https://doi.org/10.1016/j.cjca.2017.02.015
[27]
Rasmussen, P.V., Skov, M.W., Ghouse, J., Pietersen, A., Hansen, S.M., Torp-Pedersen, C., et al. (2019) Clinical Implications of Electrocardiographic Bundle Branch Block in Primary Care. Heart, 105, 1160-1167. https://doi.org/10.1136/heartjnl-2018-314295
[28]
Toufan, M., Kazemi, B. and Molazadeh, N. (2017) The Significance of the Left Atrial Volume Index in Prediction of Atrial Fibrillation Recurrence after Electrical Cardioversion. JournalofCardiovascularandThoracicResearch, 9, 54-59. https://doi.org/10.15171/jcvtr.2017.08
[29]
Akdemir, B., Altekim, R.E., Kucuk, M., Yanikoglu, A., Karakas, M.S., Aktas, A., et al. (2012) The Significance of the Left Atrial Volume Index in Cardioversion Success and Its Relationship with Recurrence in Patients with Non-Valvular Atrial Fibrillation Subjected to Electrical Cardioversion: A Study on Diagnostic Accuracy. AnadoluKardiyolojiDergisi/TheAnatolianJournalofCardiology, 13, 18-25. https://doi.org/10.5152/akd.2013.003
[30]
Van Noord, T., Van Gelder, I.C., Schoonderwoerd, B.A. and Crijns, H.J.G.M. (2000) Immediate Reinitiation of Atrial Fibrillation after Electrical Cardioversion Predicts Subsequent Pharmacologic and Electrical Conversion to Sinus Rhythm on Amiodarone. TheAmericanJournalofCardiology, 86, 1384-1385. https://doi.org/10.1016/s0002-9149(00)01250-9
[31]
Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., et al. (2012) Short-term versus Long-Term Antiarrhythmic Drug Treatment after Cardioversion of Atrial Fibrillation (Flec-SL): A Prospective, Randomised, Open-Label, Blinded Endpoint Assessment Trial. TheLancet, 380, 238-246. https://doi.org/10.1016/s0140-6736(12)60570-4
[32]
Mont, L., Bisbal, F., Hernández-Madrid, A., Pérez-Castellano, N., Viñolas, X., Arenal, A., et al. (2013) Catheter Ablation Vs. Antiarrhythmic Drug Treatment of Persistent Atrial Fibrillation: A Multicentre, Randomized, Controlled Trial (SARA Study). EuropeanHeartJournal, 35, 501-507. https://doi.org/10.1093/eurheartj/eht457
